Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.59    -0.31 (-10.69%)
Bid:
2.60
Ask:
2.91
Spread: 0.31 (11.923%)
Market Cap: £4.73m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Welcomes RoHS Report

24 Apr 2014 07:00

RNS Number : 3804F
Nanoco Group PLC
24 April 2014
 



For immediate release

24 April 2014

 

 

NANOCO GROUP PLC

("Nanoco" or "the Company")

 

Welcomes RoHS Report

 

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, welcomes the publication of a report prepared for the European Commission in connection with exemptions to the Restriction of Hazardous Substances Directive. The report recommends only a temporary exemption for the use of cadmium-containing quantum dots in displays.

 

The exemption, which had been requested by companies involved in the production of cadmium-containing quantum dots, is recommended to run only to 1 July 2017.

 

The report states: "This exemption is recommended for a shorter period than that applied for, in light of the understanding that applications resulting in reduction of cadmium quantities as well as cadmium-free substitutes are in final stages of research."

 

It is also recommended in the report that there should be no exemption at the current time for the use of cadmium-containing quantum dots in solid state lighting.

 

The report, entitled Assistance to the Commission on Technological Socio-Economic and Cost-Benefit Assessment Related to Exemptions from the Substance Restrictions in Electrical and Electronic Equipment (RoHS Directive), will now be considered by the European Commission.

 

The full text of the report is accessible at the following link: http://rohs.exemptions.oeko.info/fileadmin/user_upload/RoHS_IX/20140422_RoHS2_Evaluation_Ex_Requests_2013-1-5_final.pdf

 

 

Michael Edelman, Nanoco's Chief Executive Officer, said: "This recommendation to grant a temporary exemption for cadmium-containing quantum dots used in displays recognises that cadmium is a hazardous substance and that Nanoco has developed a cadmium-free alternative on the threshold of commercialisation. We welcome the recommendation and continue to believe that display makers will choose cadmium-free quantum dots as the preferred solution to meet their human health and environmental agendas."

 

For further information please contact:

Nanoco

+ 44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Colin White, Chief Financial Officer

 

Canaccord Genuity - Nomad and Joint Broker

+44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

 

Liberum Capital - Joint Broker

+44 (0) 20 3100 2000

Simon Atkinson

Richard Bootle

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting and solar cells. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and business development offices in the USA, Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDBGDSBSDBGSX
Date   Source Headline
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Oct 20247:00 amRNSReceipt of General Meeting Requisition Notice
23rd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Oct 20247:00 amRNSAppointment of CEO and Notice of Results
22nd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
21st Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
18th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.